Skip to main content
NCBI home page
Journal of the National Medical Association logoLink to Journal of the National Medical Association
. 2007 Jul;99(7):785–794.

The management of painful bone metastases with an emphasis on radionuclide therapy.

Darren J Hillegonds 1, Stephen Franklin 1, David K Shelton 1, Srinivasan Vijayakumar 1, Vani Vijayakumar 1
PMCID: PMC2574338  PMID: 17668645

Abstract

OBJECTIVE: This review provides an update on the management of painful bone metastases, with an emphasis on radionuclide therapy, and introduces oligometastases and quantitative imaging evaluations for clinical trials. METHODS: The current use of radionuclides, alone and in combination with chemotherapy and radiation therapy for painful bone metastases, is discussed, including toxicity, cost and overall outcomes. RESULTS: Radionuclide therapy is shown to be a useful and cost-effective means of alleviating bone pain in metastatic disease and may be more effective when combined with chemotherapy, bisphosphonates and radiation therapy. Early use of radionuclides in pain therapy may limit cancer progression by inhibiting oligometastases development. Thus, radionuclides can significantly decrease patient morbidity, prolong patient survival, and may decrease the occurrence of new bone metastases. CONCLUSION: Palliative pain therapy is critical for effectively managing bone metastases, with treatment options including analgesics, external beam radiotherapy, chemotherapy and radionuclides. Radionuclide therapy is underutilized. Recent studies using radionuclides with chemotherapy and bisphosponates, or using newer radionuclides or combinations of radionuclides and treatment paradigms (e.g., higher activities, repetitive or cyclic administration, chemo sensitization, chemo supplementation), are encouraging. A comprehensive, inter-disciplinary clinical approach is needed. Clinical collaborations will optimize radionuclide therapy for pain palliation and increase awareness of its benefits.

Full text

PDF
785

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alberts A. S., Smit B. J., Louw W. K., van Rensburg A. J., van Beek A., Kritzinger V., Nel J. S. Dose response relationship and multiple dose efficacy and toxicity of samarium-153-EDTMP in metastatic cancer to bone. Radiother Oncol. 1997 May;43(2):175–179. doi: 10.1016/s0167-8140(97)01912-9. [DOI] [PubMed] [Google Scholar]
  2. Ashayeri Ebrahim, Omogbehin Adedamola, Sridhar Rajagopalan, Shankar Ravi A. Strontium 89 in the treatment of pain due to diffuse osseous metastases: a university hospital experience. J Natl Med Assoc. 2002 Aug;94(8):706–711. [PMC free article] [PubMed] [Google Scholar]
  3. Bishayee A., Rao D. V., Srivastava S. C., Bouchet L. G., Bolch W. E., Howell R. W. Marrow-sparing effects of 117mSn(4+)diethylenetriaminepentaacetic acid for radionuclide therapy of bone cancer. J Nucl Med. 2000 Dec;41(12):2043–2050. [PubMed] [Google Scholar]
  4. Blake G. M., Zivanovic M. A., McEwan A. J., Ackery D. M. Sr-89 therapy: strontium kinetics in disseminated carcinoma of the prostate. Eur J Nucl Med. 1986;12(9):447–454. doi: 10.1007/BF00254749. [DOI] [PubMed] [Google Scholar]
  5. Blitzer P. H. Reanalysis of the RTOG study of the palliation of symptomatic osseous metastasis. Cancer. 1985 Apr 1;55(7):1468–1472. doi: 10.1002/1097-0142(19850401)55:7<1468::aid-cncr2820550708>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
  6. Body J. J., Bartl R., Burckhardt P., Delmas P. D., Diel I. J., Fleisch H., Kanis J. A., Kyle R. A., Mundy G. R., Paterson A. H. Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J Clin Oncol. 1998 Dec;16(12):3890–3899. doi: 10.1200/JCO.1998.16.12.3890. [DOI] [PubMed] [Google Scholar]
  7. Bonica J. J. Importance of effective pain control. Acta Anaesthesiol Scand Suppl. 1987;85:1–16. doi: 10.1111/j.1399-6576.1987.tb02665.x. [DOI] [PubMed] [Google Scholar]
  8. Bouchet L. G., Bolch W. E., Goddu S. M., Howell R. W., Rao D. V. Considerations in the selection of radiopharmaceuticals for palliation of bone pain from metastatic osseous lesions. J Nucl Med. 2000 Apr;41(4):682–687. [PubMed] [Google Scholar]
  9. Breen S. L., Powe J. E., Porter A. T. Dose estimation in strontium-89 radiotherapy of metastatic prostatic carcinoma. J Nucl Med. 1992 Jul;33(7):1316–1323. [PubMed] [Google Scholar]
  10. Brenner W., Kampen W. U., Kampen A. M., Henze E. Skeletal uptake and soft-tissue retention of 186Re-HEDP and 153Sm-EDTMP in patients with metastatic bone disease. J Nucl Med. 2001 Feb;42(2):230–236. [PubMed] [Google Scholar]
  11. Brown Janet E., Cook Richard J., Major Pierre, Lipton Allan, Saad Fred, Smith Matthew, Lee Ker-Ai, Zheng Ming, Hei Yong-Jiang, Coleman Robert E. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst. 2005 Jan 5;97(1):59–69. doi: 10.1093/jnci/dji002. [DOI] [PubMed] [Google Scholar]
  12. Buffa Francesca M., Flux Glenn D., Guy Matt J., O'Sullivan Joe M., McCready Victor R., Chittenden Sarah J., Dearnaley David P. A model-based method for the prediction of whole-body absorbed dose and bone marrow toxicity for 186Re-HEDP treatment of skeletal metastases from prostate cancer. Eur J Nucl Med Mol Imaging. 2003 May 22;30(8):1114–1124. doi: 10.1007/s00259-003-1197-y. [DOI] [PubMed] [Google Scholar]
  13. Burnet N. G., Williams G., Howard N. Phosphorus-32 for intractable bony pain from carcinoma of the prostate. Clin Oncol (R Coll Radiol) 1990 Jul;2(4):220–223. doi: 10.1016/s0936-6555(05)80172-4. [DOI] [PubMed] [Google Scholar]
  14. Clark G. M., Sledge G. W., Jr, Osborne C. K., McGuire W. L. Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol. 1987 Jan;5(1):55–61. doi: 10.1200/JCO.1987.5.1.55. [DOI] [PubMed] [Google Scholar]
  15. Coleman R. E. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev. 2001 Jun;27(3):165–176. doi: 10.1053/ctrv.2000.0210. [DOI] [PubMed] [Google Scholar]
  16. Coleman R. E. Should bisphosphonates be the treatment of choice for metastatic bone disease? Semin Oncol. 2001 Aug;28(4 Suppl 11):35–41. doi: 10.1016/s0093-7754(01)90230-1. [DOI] [PubMed] [Google Scholar]
  17. Coleman Robert E., Major Pierre, Lipton Allan, Brown Janet E., Lee Ker-Ai, Smith Matthew, Saad Fred, Zheng Ming, Hei Yong Jiang, Seaman John. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol. 2005 Jun 27;23(22):4925–4935. doi: 10.1200/JCO.2005.06.091. [DOI] [PubMed] [Google Scholar]
  18. Collins C., Eary J. F., Donaldson G., Vernon C., Bush N. E., Petersdorf S., Livingston R. B., Gordon E. E., Chapman C. R., Appelbaum F. R. Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial. J Nucl Med. 1993 Nov;34(11):1839–1844. [PubMed] [Google Scholar]
  19. Dafermou A., Colamussi P., Giganti M., Cittanti C., Bestagno M., Piffanelli A. A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer. Eur J Nucl Med. 2001 Jul;28(7):788–798. doi: 10.1007/s002590100533. [DOI] [PubMed] [Google Scholar]
  20. Damerla Venugopal, Packianathan S., Boerner Philip S., Jani Ashesh B., Vijayakumar Srinivasan, Vijayakumar Vani. Recent developments in nuclear medicine in the management of bone metastases: a review and perspective. Am J Clin Oncol. 2005 Oct;28(5):513–520. doi: 10.1097/01.coc.0000162425.55457.10. [DOI] [PubMed] [Google Scholar]
  21. Das Tapas, Chakraborty Sudipta, Unni P. R., Banerjee Sharmila, Samuel Grace, Sarma H. D., Venkatesh Meera, Pillai M. R. A. 177Lu-labeled cyclic polyaminophosphonates as potential agents for bone pain palliation. Appl Radiat Isot. 2002 Aug;57(2):177–184. doi: 10.1016/s0969-8043(02)00104-5. [DOI] [PubMed] [Google Scholar]
  22. Dolezal J. Systemic radionuclide therapy with Samarium-153-EDTMP for painful bone metastases. Nucl Med Rev Cent East Eur. 2000;3(2):161–163. [PubMed] [Google Scholar]
  23. Fitzgerald Robert L., Hillegonds Darren J., Burton Douglas W., Griffin Terrance L., Mullaney Scott, Vogel John S., Deftos Leonard J., Herold David A. 41Ca and accelerator mass spectrometry to monitor calcium metabolism in end stage renal disease patients. Clin Chem. 2005 Sep 1;51(11):2095–2102. doi: 10.1373/clinchem.2005.049650. [DOI] [PubMed] [Google Scholar]
  24. Friedland J. Local and systemic radiation for palliation of metastatic disease. Urol Clin North Am. 1999 May;26(2):391-402, x. doi: 10.1016/s0094-0143(05)70078-1. [DOI] [PubMed] [Google Scholar]
  25. Goddu S. M., Bishayee A., Bouchet L. G., Bolch W. E., Rao D. V., Howell R. W. Marrow toxicity of 33P-versus 32P-orthophosphate: implications for therapy of bone pain and bone metastases. J Nucl Med. 2000 May;41(5):941–951. [PubMed] [Google Scholar]
  26. Gunawardana Dishan H., Lichtenstein Meir, Better Nathan, Rosenthal Mark. Results of strontium-89 therapy in patients with prostate cancer resistant to chemotherapy. Clin Nucl Med. 2004 Feb;29(2):81–85. doi: 10.1097/01.rlu.0000109721.58471.44. [DOI] [PubMed] [Google Scholar]
  27. Hamdy N. A., Papapoulos S. E. The palliative management of skeletal metastases in prostate cancer: use of bone-seeking radionuclides and bisphosphonates. Semin Nucl Med. 2001 Jan;31(1):62–68. doi: 10.1053/snuc.2001.18767. [DOI] [PubMed] [Google Scholar]
  28. Hellman S., Weichselbaum R. R. Oligometastases. J Clin Oncol. 1995 Jan;13(1):8–10. doi: 10.1200/JCO.1995.13.1.8. [DOI] [PubMed] [Google Scholar]
  29. Hoskin P. J. Radiotherapy in the management of bone pain. Clin Orthop Relat Res. 1995 Mar;(312):105–119. [PubMed] [Google Scholar]
  30. Jemal Ahmedin, Murray Taylor, Samuels Alicia, Ghafoor Asma, Ward Elizabeth, Thun Michael J. Cancer statistics, 2003. CA Cancer J Clin. 2003 Jan-Feb;53(1):5–26. doi: 10.3322/canjclin.53.1.5. [DOI] [PubMed] [Google Scholar]
  31. Jordan V. Craig, Morrow Monica. Chemoprevention of breast cancer: a model for change. J Clin Oncol. 2002 Jan 1;20(1):1–3. doi: 10.1200/JCO.2002.20.1.1. [DOI] [PubMed] [Google Scholar]
  32. Kanis J. A., McCloskey E. V. Bone turnover and biochemical markers in malignancy. Cancer. 1997 Oct 15;80(8 Suppl):1538–1545. doi: 10.1002/(sici)1097-0142(19971015)80:8+<1538::aid-cncr3>3.3.co;2-v. [DOI] [PubMed] [Google Scholar]
  33. Kasalický J., Krajská V. The effect of repeated strontium-89 chloride therapy on bone pain palliation in patients with skeletal cancer metastases. Eur J Nucl Med. 1998 Oct;25(10):1362–1367. doi: 10.1007/s002590050309. [DOI] [PubMed] [Google Scholar]
  34. Kosuda Shigeru, Yoshimura Ichiro, Aizawa Taku, Koizumi Kiyoshi, Akakura Koichiro, Kuyama Junpei, Ichihara Kiyoshi, Yonese Junji, Koizumi Mitsuru, Nakashima Jun. Can initial prostate specific antigen determinations eliminate the need for bone scans in patients with newly diagnosed prostate carcinoma? A multicenter retrospective study in Japan. Cancer. 2002 Feb 15;94(4):964–972. [PubMed] [Google Scholar]
  35. Kraeber-Bodéré F., Campion L., Rousseau C., Bourdin S., Chatal J. F., Resche I. Treatment of bone metastases of prostate cancer with strontium-89 chloride: efficacy in relation to the degree of bone involvement. Eur J Nucl Med. 2000 Oct;27(10):1487–1493. doi: 10.1007/s002590000315. [DOI] [PubMed] [Google Scholar]
  36. Laing A. H., Ackery D. M., Bayly R. J., Buchanan R. B., Lewington V. J., McEwan A. J., Macleod P. M., Zivanovic M. A. Strontium-89 chloride for pain palliation in prostatic skeletal malignancy. Br J Radiol. 1991 Sep;64(765):816–822. doi: 10.1259/0007-1285-64-765-816. [DOI] [PubMed] [Google Scholar]
  37. Leong C., McKenzie M. R., Coupland D. B., Gascoyne R. D. Disseminated intravascular coagulation in a patient with metastatic prostate cancer: fatal outcome following strontium-89 therapy. J Nucl Med. 1994 Oct;35(10):1662–1664. [PubMed] [Google Scholar]
  38. MAXFIELD J. R., Jr, MAXFIELD J. G., MAXFIELD W. S. The use of radioactive phosphorus and testosterone in metastatic bone lesions from breast and prostate. South Med J. 1958 Mar;51(3):320–327. doi: 10.1097/00007611-195803000-00009. [DOI] [PubMed] [Google Scholar]
  39. Macklis R., Lasher J. Palliative radiotherapy for skeletal metastases: cost-substitution analyses and economic impact. J Oncol Manag. 1999 Mar-Apr;8(2):17–22. [PubMed] [Google Scholar]
  40. Malmberg I., Persson U., Ask A., Tennvall J., Abrahamsson P. A. Painful bone metastases in hormone-refractory prostate cancer: economic costs of strontium-89 and/or external radiotherapy. Urology. 1997 Nov;50(5):747–753. doi: 10.1016/S0090-4295(97)00326-9. [DOI] [PubMed] [Google Scholar]
  41. Mathew Boby, Chakraborty Sudipta, Das Tapas, Sarma H. D., Banerjee Sharmila, Samuel Grace, Venkatesh Meera, Pillai M. R. A. 175Yb labeled polyaminophosphonates as potential agents for bone pain palliation. Appl Radiat Isot. 2004 May;60(5):635–642. doi: 10.1016/j.apradiso.2003.09.016. [DOI] [PubMed] [Google Scholar]
  42. Matthay K. K., Panina C., Huberty J., Price D., Glidden D. V., Tang H. R., Hawkins R. A., Veatch J., Hasegawa B. Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with (131)I-MIBG. J Nucl Med. 2001 Nov;42(11):1713–1721. [PubMed] [Google Scholar]
  43. Maxon H. R., Deutsch E. A., Thomas S. R., Libson K., Lukes S. J., Williams C. C., Ali S. Re-186(Sn) HEDP for treatment of multiple metastatic foci in bone: human biodistribution and dosimetric studies. Radiology. 1988 Feb;166(2):501–507. doi: 10.1148/radiology.166.2.3122267. [DOI] [PubMed] [Google Scholar]
  44. McEwan A. J. Use of radionuclides for the palliation of bone metastases. Semin Radiat Oncol. 2000 Apr;10(2):103–114. doi: 10.1016/s1053-4296(00)80047-8. [DOI] [PubMed] [Google Scholar]
  45. Michaelson M. Dror, Smith Matthew R. Genitourinary malignancies. Cancer Chemother Biol Response Modif. 2003;21:547–564. doi: 10.1016/s0921-4410(03)21026-7. [DOI] [PubMed] [Google Scholar]
  46. Nair N. Relative efficacy of 32P and 89Sr in palliation in skeletal metastases. J Nucl Med. 1999 Feb;40(2):256–261. [PubMed] [Google Scholar]
  47. Nielsen O. S., Munro A. J., Tannock I. F. Bone metastases: pathophysiology and management policy. J Clin Oncol. 1991 Mar;9(3):509–524. doi: 10.1200/JCO.1991.9.3.509. [DOI] [PubMed] [Google Scholar]
  48. Nilsson Sten, Larsen Roy H., Fosså Sophie D., Balteskard Lise, Borch Kari W., Westlin Jan-Erik, Salberg Gro, Bruland Oyvind S. First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res. 2005 Jun 15;11(12):4451–4459. doi: 10.1158/1078-0432.CCR-04-2244. [DOI] [PubMed] [Google Scholar]
  49. Noguchi M., Kikuchi H., Ishibashi M., Noda S. Percentage of the positive area of bone metastasis is an independent predictor of disease death in advanced prostate cancer. Br J Cancer. 2003 Jan 27;88(2):195–201. doi: 10.1038/sj.bjc.6600715. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. O'Sullivan J. M., McCready V. R., Flux G., Norman A. R., Buffa F. M., Chittenden S., Guy M., Pomeroy K., Cook G., Gadd J. High activity Rhenium-186 HEDP with autologous peripheral blood stem cell rescue: a phase I study in progressive hormone refractory prostate cancer metastatic to bone. Br J Cancer. 2002 Jun 5;86(11):1715–1720. doi: 10.1038/sj.bjc.6600348. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Palmedo H., Bender H., Schomburg A., Grünwald F., Schöneich G., Zamorra P., Reichmann K., Dierke-Dzierzon C., Mallmann P., Biersack H. J. Schmerztherapie mit Rhenium-186 HEDP bei multiplen Knochenmetastasen. Nuklearmedizin. 1996 Apr;35(2):63–67. [PubMed] [Google Scholar]
  52. Pandit-Taskar Neeta, Batraki Maria, Divgi Chaitanya R. Radiopharmaceutical therapy for palliation of bone pain from osseous metastases. J Nucl Med. 2004 Aug;45(8):1358–1365. [PubMed] [Google Scholar]
  53. Papatheofanis F. J. Variation in oncologic opinion regarding management of metastatic bone pain with systemic radionuclide therapy. J Nucl Med. 1999 Sep;40(9):1420–1423. [PubMed] [Google Scholar]
  54. Piffanelli A., Dafermou A., Giganti M., Colamussi P., Pizzocaro C., Bestagno M., Italian Association of Nuclear Medicine (AINM) Radionuclide therapy for painful bone metastases. An Italian multicentre observational study. Writing Committee of an Ad Hoc Study Group. Q J Nucl Med. 2001 Mar;45(1):100–107. [PubMed] [Google Scholar]
  55. Porter A. T., McEwan A. J., Powe J. E., Reid R., McGowan D. G., Lukka H., Sathyanarayana J. R., Yakemchuk V. N., Thomas G. M., Erlich L. E. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys. 1993 Apr 2;25(5):805–813. doi: 10.1016/0360-3016(93)90309-j. [DOI] [PubMed] [Google Scholar]
  56. Quilty P. M., Kirk D., Bolger J. J., Dearnaley D. P., Lewington V. J., Mason M. D., Reed N. S., Russell J. M., Yardley J. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol. 1994 Apr;31(1):33–40. doi: 10.1016/0167-8140(94)90411-1. [DOI] [PubMed] [Google Scholar]
  57. Resche I., Chatal J. F., Pecking A., Ell P., Duchesne G., Rubens R., Fogelman I., Houston S., Fauser A., Fischer M. A dose-controlled study of 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases. Eur J Cancer. 1997 Sep;33(10):1583–1591. doi: 10.1016/s0959-8049(97)00155-x. [DOI] [PubMed] [Google Scholar]
  58. Robinson R. G., Blake G. M., Preston D. F., McEwan A. J., Spicer J. A., Martin N. L., Wegst A. V., Ackery D. M. Strontium-89: treatment results and kinetics in patients with painful metastatic prostate and breast cancer in bone. Radiographics. 1989 Mar;9(2):271–281. doi: 10.1148/radiographics.9.2.2467331. [DOI] [PubMed] [Google Scholar]
  59. Roodman G. David. Mechanisms of bone metastasis. N Engl J Med. 2004 Apr 15;350(16):1655–1664. doi: 10.1056/NEJMra030831. [DOI] [PubMed] [Google Scholar]
  60. Sabbatini P., Larson S. M., Kremer A., Zhang Z. F., Sun M., Yeung H., Imbriaco M., Horak I., Conolly M., Ding C. Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol. 1999 Mar;17(3):948–957. doi: 10.1200/JCO.1999.17.3.948. [DOI] [PubMed] [Google Scholar]
  61. Salazar O. M., Rubin P., Hendrickson F. R., Komaki R., Poulter C., Newall J., Asbell S. O., Mohiuddin M., Van Ess J. Single-dose half-body irradiation for palliation of multiple bone metastases from solid tumors. Final Radiation Therapy Oncology Group report. Cancer. 1986 Jul 1;58(1):29–36. doi: 10.1002/1097-0142(19860701)58:1<29::aid-cncr2820580107>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]
  62. Sandeman T. F., Budd R. S., Martin J. J. Samarium-153-labelled EDTMP for bone metastases from cancer of the prostate. Clin Oncol (R Coll Radiol) 1992 May;4(3):160–164. doi: 10.1016/s0936-6555(05)81078-7. [DOI] [PubMed] [Google Scholar]
  63. Schulte M., Brecht-Krauss D., Heymer B., Guhlmann A., Hartwig E., Sarkar M. R., Diederichs C. G., Von Baer A., Kotzerke J., Reske S. N. Grading of tumors and tumorlike lesions of bone: evaluation by FDG PET. J Nucl Med. 2000 Oct;41(10):1695–1701. [PubMed] [Google Scholar]
  64. Sciuto R., Festa A., Pasqualoni R., Semprebene A., Rea S., Bergomi S., Maini C. L. Metastatic bone pain palliation with 89-Sr and 186-Re-HEDP in breast cancer patients. Breast Cancer Res Treat. 2001 Mar;66(2):101–109. doi: 10.1023/a:1010658522847. [DOI] [PubMed] [Google Scholar]
  65. Sciuto R., Tofani A., Festa A., Giannarelli D., Pasqualoni R., Maini C. L. Short- and long-term effects of 186Re-1,1-hydroxyethylidene diphosphonate in the treatment of painful bone metastases. J Nucl Med. 2000 Apr;41(4):647–654. [PubMed] [Google Scholar]
  66. Sciuto Rosa, Festa Anna, Rea Sandra, Pasqualoni Rosella, Bergomi Serenella, Petrilli Germana, Maini Carlo L. Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial. J Nucl Med. 2002 Jan;43(1):79–86. [PubMed] [Google Scholar]
  67. Serafini A. N., Houston S. J., Resche I., Quick D. P., Grund F. M., Ell P. J., Bertrand A., Ahmann F. R., Orihuela E., Reid R. H. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol. 1998 Apr;16(4):1574–1581. doi: 10.1200/JCO.1998.16.4.1574. [DOI] [PubMed] [Google Scholar]
  68. Serafini A. N. Therapy of metastatic bone pain. J Nucl Med. 2001 Jun;42(6):895–906. [PubMed] [Google Scholar]
  69. Shah Syed G. M., Maken R. N., Muzzaffar N., Shah M. A., Rana F. Effective and economical option for pain palliation in prostate cancer with skeletal metastases: 32P therapy revisited. Nucl Med Commun. 1999 Aug;20(8):697–702. doi: 10.1097/00006231-199908000-00003. [DOI] [PubMed] [Google Scholar]
  70. Silberstein E. B., Elgazzar A. H., Kapilivsky A. Phosphorus-32 radiopharmaceuticals for the treatment of painful osseous metastases. Semin Nucl Med. 1992 Jan;22(1):17–27. doi: 10.1016/s0001-2998(05)80153-9. [DOI] [PubMed] [Google Scholar]
  71. Silberstein E. B., Elgazzar A. H., Kapilivsky A. Phosphorus-32 radiopharmaceuticals for the treatment of painful osseous metastases. Semin Nucl Med. 1992 Jan;22(1):17–27. doi: 10.1016/s0001-2998(05)80153-9. [DOI] [PubMed] [Google Scholar]
  72. Silberstein E. B. Systemic radiopharmaceutical therapy of painful osteoblastic metastases. Semin Radiat Oncol. 2000 Jul;10(3):240–249. doi: 10.1053/srao.2000.6592. [DOI] [PubMed] [Google Scholar]
  73. Silberstein E. B. The treatment of painful osseous metastases with phosphorus-32-labeled phosphates. Semin Oncol. 1993 Jun;20(3 Suppl 2):10–21. [PubMed] [Google Scholar]
  74. Silberstein E., Taylor A., Jr Procedure guideline for bone pain treatment: 1.0. Society of Nuclear Medicine. J Nucl Med. 1996 May;37(5):881–884. [PubMed] [Google Scholar]
  75. Silberstein Edward B. Teletherapy and radiopharmaceutical therapy of painful bone metastases. Semin Nucl Med. 2005 Apr;35(2):152–158. doi: 10.1053/j.semnuclmed.2004.11.006. [DOI] [PubMed] [Google Scholar]
  76. Singh A., Holmes R. A., Farhangi M., Volkert W. A., Williams A., Stringham L. M., Ketring A. R. Human pharmacokinetics of samarium-153 EDTMP in metastatic cancer. J Nucl Med. 1989 Nov;30(11):1814–1818. [PubMed] [Google Scholar]
  77. Singh Deepinder, Yi Won Sam, Brasacchio Ralph A., Muhs Ann G., Smudzin Therese, Williams Jacqueline P., Messing Edward, Okunieff Paul. Is there a favorable subset of patients with prostate cancer who develop oligometastases? Int J Radiat Oncol Biol Phys. 2004 Jan 1;58(1):3–10. doi: 10.1016/s0360-3016(03)01442-1. [DOI] [PubMed] [Google Scholar]
  78. Soerdjbalie-Maikoe Vidya, Pelger Rob C. M., Lycklama à Nijeholt Guus A. B., Arndt Jan-Willem, Zwinderman Aeilko H., Papapoulos Socrates E., Hamdy Neveen A. T. Strontium-89 (Metastron) and the bisphosphonate olpadronate reduce the incidence of spinal cord compression in patients with hormone-refractory prostate cancer metastatic to the skeleton. Eur J Nucl Med Mol Imaging. 2002 Feb 15;29(4):494–498. doi: 10.1007/s00259-001-0728-7. [DOI] [PubMed] [Google Scholar]
  79. Solomayer E. F., Diel I. J., Meyberg G. C., Gollan C., Bastert G. Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis. Breast Cancer Res Treat. 2000 Feb;59(3):271–278. doi: 10.1023/a:1006308619659. [DOI] [PubMed] [Google Scholar]
  80. Soloway M. S., Hardeman S. W., Hickey D., Raymond J., Todd B., Soloway S., Moinuddin M. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer. 1988 Jan 1;61(1):195–202. doi: 10.1002/1097-0142(19880101)61:1<195::aid-cncr2820610133>3.0.co;2-y. [DOI] [PubMed] [Google Scholar]
  81. Srivastava S. C., Atkins H. L., Krishnamurthy G. T., Zanzi I., Silberstein E. B., Meinken G., Mausner L. F., Swailem F., D'Alessandro T., Cabahug C. J. Treatment of metastatic bone pain with tin-117m Stannic diethylenetriaminepentaacetic acid: a phase I/II clinical study. Clin Cancer Res. 1998 Jan;4(1):61–68. [PubMed] [Google Scholar]
  82. Tang Binwu, Vu Mary, Booker Timberly, Santner Steven J., Miller Fred R., Anver Miriam R., Wakefield Lalage M. TGF-beta switches from tumor suppressor to prometastatic factor in a model of breast cancer progression. J Clin Invest. 2003 Oct;112(7):1116–1124. doi: 10.1172/JCI18899. [DOI] [PMC free article] [PubMed] [Google Scholar]
  83. Tian J. H., Zhang J. M., Hou Q. T., Oyang Q. H., Wang J. M., Luan Z. S., Chuan L., He Y. J. Multicentre trial on the efficacy and toxicity of single-dose samarium-153-ethylene diamine tetramethylene phosphonate as a palliative treatment for painful skeletal metastases in China. Eur J Nucl Med. 1999 Jan;26(1):2–7. doi: 10.1007/s002590050351. [DOI] [PubMed] [Google Scholar]
  84. Turner J. H., Claringbold P. G. A phase II study of treatment of painful multifocal skeletal metastases with single and repeated dose samarium-153 ethylenediaminetetramethylene phosphonate. Eur J Cancer. 1991;27(9):1084–1086. doi: 10.1016/0277-5379(91)90297-q. [DOI] [PubMed] [Google Scholar]
  85. Turner J. H., Claringbold P. G. A phase II study of treatment of painful multifocal skeletal metastases with single and repeated dose samarium-153 ethylenediaminetetramethylene phosphonate. Eur J Cancer. 1991;27(9):1084–1086. doi: 10.1016/0277-5379(91)90297-q. [DOI] [PubMed] [Google Scholar]
  86. Turner J. H., Martindale A. A., Sorby P., Hetherington E. L., Fleay R. F., Hoffman R. F., Claringbold P. G. Samarium-153 EDTMP therapy of disseminated skeletal metastasis. Eur J Nucl Med. 1989;15(12):784–795. doi: 10.1007/BF00255498. [DOI] [PubMed] [Google Scholar]
  87. Turner S. L., Gruenewald S., Spry N., Gebski V., Metastron Users Group Less pain does equal better quality of life following strontium-89 therapy for metastatic prostate cancer. Br J Cancer. 2001 Feb 2;84(3):297–302. doi: 10.1054/bjoc.2000.1610. [DOI] [PMC free article] [PubMed] [Google Scholar]
  88. Volkert W. A., Hoffman T. J. Therapeutic radiopharmaceuticals. Chem Rev. 1999 Sep 8;99(9):2269–2292. doi: 10.1021/cr9804386. [DOI] [PubMed] [Google Scholar]
  89. Woo Sook-Bin, Hellstein John W., Kalmar John R. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006 May 16;144(10):753–761. doi: 10.7326/0003-4819-144-10-200605160-00009. [DOI] [PubMed] [Google Scholar]
  90. Yau Vivian, Chow Edward, Davis Lori, Holden Lori, Schueller Trudi, Danjoux Cyril. Pain management in cancer patients with bone metastases remains a challenge. J Pain Symptom Manage. 2004 Jan;27(1):1–3. doi: 10.1016/j.jpainsymman.2003.10.003. [DOI] [PubMed] [Google Scholar]
  91. Zeevaart Jan R., Louw Werner K. A., Kolar Zvonimir I., Kilian Elmaré, van Rensburg Frederika E. Jansen, Dormehl Irene C. Biodistribution and pharmacokinetics of variously molecular sized 117mSn(II)-polyethyleneiminomethyl phosphonate complexes in the normal primate model as potential selective therapeutic bone agents. Arzneimittelforschung. 2004;54(6):340–347. doi: 10.1055/s-0031-1296981. [DOI] [PubMed] [Google Scholar]
  92. Zhang Hong, Tian Mei, Li Sijing, Liu Jianzhong, Tanada Syuji, Endo Keigo. Rhenium-188-HEDP therapy for the palliation of pain due to osseous metastases in lung cancer patients. Cancer Biother Radiopharm. 2003 Oct;18(5):719–726. doi: 10.1089/108497803770418265. [DOI] [PubMed] [Google Scholar]

Articles from Journal of the National Medical Association are provided here courtesy of National Medical Association

RESOURCES